AngioDynamics (NSDQ:ANGO) shares ticked up this morning on fourth-quarter results that beat the consensus revenue forecast.
The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of -$19.5 million, or -51¢ per share, on sales of $76.8 million for the three months ended May 31, 2021, for an 87.6% bottom-line gain on sales growth of 31.7%.
